Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd (OKYO) was submitted on August 23, 2024. The report discloses a significant transaction involving the Executive Chairman, Gabriele Cerrone, and an entity in which he holds a beneficial interest.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share purchase transaction.
- Transaction Price: US$1.05 per share.
- Shares Purchased: 50,000 ordinary shares.
- Market: NASDAQ.
Material Changes
The primary material change reported is the increase in share ownership by an entity affiliated with the Executive Chairman.
- Purchaser: Panetta Partners Limited (an entity with a beneficial interest held by Gabriele Cerrone, Executive Chairman).
- Updated Ownership: Following the purchase, Mr. Cerrone's total shareholding stands at 9,721,570 shares.
- Ownership Percentage: This represents 28.73% of the Company's issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It serves strictly as a notification of the share acquisition and includes a standard disclaimer that the attached announcement is furnished but not "filed" for liability purposes under Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the exact beneficial interest structure of Gabriele Cerrone in Panetta Partners Limited.
- Confirm the total issued share capital of OKYO Pharma Ltd to validate the 28.73% ownership calculation.
- Review the attached Exhibit 99.1 (News Announcement) for any additional context regarding the transaction not included in the Form 6-K summary.
- Check recent trading volumes on NASDAQ to assess the impact of this 50,000 share purchase on market liquidity.